Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ONO-8430506 是一种可口服的、具有有效性的 autotaxin (ATX)/ENPP2 抑制剂( IC90 :100 nM),能够抑制小鼠血浆中 ATX 活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,480 | 现货 | ||
2 mg | ¥ 3,680 | 现货 | ||
5 mg | ¥ 5,970 | 现货 | ||
10 mg | ¥ 8,130 | 现货 | ||
25 mg | ¥ 11,800 | 现货 | ||
50 mg | ¥ 16,200 | 现货 | ||
100 mg | ¥ 21,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 6,520 | 现货 |
产品描述 | ONO-8430506 is an orally available, potent autotaxin (ATX)/ENPP2 inhibitor (IC90: 100 nM) that inhibits ATX activity in mouse plasma. |
靶点活性 | ATX/ENPP2:100 nM |
体外活性 |
The IC50 values of ONO-8430506 against the lysophospholipase D (LysoPLD) activity of recombinant human ATX/ENPP2 are 5.1 nM and 4.5 nM, determined using synthetic fluorescent substrate (FS-3) and a natural substrate (16:0-LPC) assay, respectively.[2] ONO-8430506 exhibits effective inhibition of lysophosphatidic acid (LPA) formation, demonstrating IC50 values of approximately 10 nM with both recombinant and plasma-derived ATX/ENPP2 derived from diverse animal species.[2] |
体内活性 |
ONO-8430506 (10 mg/kg/day; gavage; for 21 days). Tumor growth in ONO-8430506-treated mice caught up to the vehicle group by day 13; thereafter, primary tumor size was not significantly different from the vehicle-treated mice. It can slows initial tumor growth and limits lung metastasis. ONO-8430506 decreases the initial phase of breast tumor growth and subsequent lung metastases by ~60% in a syngeneic orthotopic mouse model.[1] ONO-8430506 (oral; 30 mg/kg) demonstrates good pharmacokinetics and persistently inhibits plasma lysophosphatidic acid formation in rats.[2] ONO-8430506 (30 or 100 mg/kg) enhances the antitumor effect of Paclitaxel in a breast cancer model.[3] ONO-8430506 exhibits moderate oral bioavailability (rat 51.6%, dog 71.1%, and monkey 30.8%) and C max (rat 261, dog 1670, and monkey 63 ng/mL) following oral administration (rat 1, dog 1, and monkey 1 mg/kg).[3] |
分子量 | 461.53 |
分子式 | C27H28FN3O3 |
CAS No. | 1354805-08-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (195.0 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1667 mL | 10.8335 mL | 21.6671 mL | 54.1677 mL |
5 mM | 0.4333 mL | 2.1667 mL | 4.3334 mL | 10.8335 mL | |
10 mM | 0.2167 mL | 1.0834 mL | 2.1667 mL | 5.4168 mL | |
20 mM | 0.1083 mL | 0.5417 mL | 1.0834 mL | 2.7084 mL | |
50 mM | 0.0433 mL | 0.2167 mL | 0.4333 mL | 1.0834 mL | |
100 mM | 0.0217 mL | 0.1083 mL | 0.2167 mL | 0.5417 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ONO-8430506 1354805-08-5 Metabolism PDE ONO 8430506 ONO8430506 Inhibitor inhibitor inhibit